Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-14T15:13:15.457Z Has data issue: false hasContentIssue false
  • English
  • Français

Orosomucoid influences both antidepressant tolerance and response

Published online by Cambridge University Press:  24 June 2014

J Harley,
R Roberts,
P Joyce,
R Mulder,
S Luty,
C Frampton and
M Kennedy
J Harley
Affiliation:
Christchurch School of Medicine and Health Sciences, University of Otago, New Zealand
R Roberts
Affiliation:
Christchurch School of Medicine and Health Sciences, University of Otago, New Zealand
P Joyce
Affiliation:
Christchurch School of Medicine and Health Sciences, University of Otago, New Zealand
R Mulder
Affiliation:
Christchurch School of Medicine and Health Sciences, University of Otago, New Zealand
S Luty
Affiliation:
Christchurch School of Medicine and Health Sciences, University of Otago, New Zealand
C Frampton
Affiliation:
Christchurch School of Medicine and Health Sciences, University of Otago, New Zealand
M Kennedy
Affiliation:
Christchurch School of Medicine and Health Sciences, University of Otago, New Zealand
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Information

Type
Abstracts from ‘Brainwaves’— The Australasian Society for Psychiatric Research Annual Meeting 2006, 6–8 December, Sydney, Australia
Information
Acta Neuropsychiatrica , Volume 18 , Issue 6 , December 2006, pp. 291
Copyright
Copyright © 2006 Blackwell Munksgaard

Background:

Orosomucoid, an acute-phase reactant (APR), carries basic drugs including antidepressants. Elevated levels have been reported in depressed patients. It has yet to be established whether concentration influences antidepressant response. Its gene, ORMI, is polymorphic and has three common codomi-nant alleles ORM*F1, *F2 and *S. The variants have differing pharmacokinetic properties that potentially alter plasma profile and blood-brain barrier transport of antidepressants influencing tolerance and efficacy.

Methods:

A total of 157 out-patients in a trial of fluoxetine vs. nortriptyline were genotyped for the ORMl variants. Plasma concentrations of APRs were also measured. Outcomes were tolerance and response. Tolerance was defined as the completion of a 6-week trial and response as an improvement of greater than 60% on the Montgomery-Asperg Depression Rating Scale at 6 weeks. Groups were compared using one-way ANOVA and chi-squared tests. Outcome predictions were performed using binomial logistic regression.

Results:

Individuals with an ORM1*F allele were more likely to tolerate antidepressants [odds ratio (OR) = 4.707, 95% confidence interval (CI) 1.769−12.527, P = 0.002). Higher orosomucoid concentrations were found in antidepressant nonresponders (91.4% vs. 79.1%, F-stat 6.071, P = 0.015). For every 1% increase in orosomucoid, the odds of response were decreased (OR = 0.984, 95% CI 0.971−0.997, P = 0.018).

Conclusions:

The two effects of orosomucoid – polymorphism affecting tolerability and concentration affecting efficacy – emphasize its importance in the handling of antidepressants.